Startups
2022
SUCCIPRO SLEXPLOIT THE SUCCINATE-METABOLIC-INFLAMMATORY AXIS TO CREATE NOVEL, FIRST-IN CLASS THERAPEUTICS FOR INFLAMMATORY AND METABOLIC DISEASES
Unique propietary tools to generate a pipeline of pre-clinical candidates with a focus on inflammatory and metabolic diseases.
Unique propietary tools to generate a pipeline of pre-clinical candidates with a focus on inflammatory and metabolic diseases.
Address
Carrer Doctor Mallafré Guasch 4, 43005 Tarragona, Spain
CERCA ownership
Reus, Spain
2005
Institut de Recerca Biomèdica Catalunya Sud (IRB CatSud)
Other Catalan Public owners
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
OUR MISSION
Carry out the preclinical and early clinical development of succinate-modulating therapies for inflammatory and metabolic diseases, particularly obesity, type 2 diabetes and Crohn’s disease.
OUR VISION
Contribute to the long-term health of the people through science and provide effective solutions to people suffering from illnesses with a strong chronic inflammatory component by lowering succinate levels.
OUR STORY
SUCCIPRO is a project born from solid science on succinate pathophysiology from the DIAMET Research group (www.diamet.org), located at IISPV (www.IISPV.cat). SUCCIPRO is exclussively focused on succinate-modulating therapies.
Carry out the preclinical and early clinical development of succinate-modulating therapies for inflammatory and metabolic diseases, particularly obesity, type 2 diabetes and Crohn’s disease.
OUR VISION
Contribute to the long-term health of the people through science and provide effective solutions to people suffering from illnesses with a strong chronic inflammatory component by lowering succinate levels.
OUR STORY
SUCCIPRO is a project born from solid science on succinate pathophysiology from the DIAMET Research group (www.diamet.org), located at IISPV (www.IISPV.cat). SUCCIPRO is exclussively focused on succinate-modulating therapies.
Product description
Since succinate is elevated in many pathological situations with a metabolic and/or a inflammatory component, we are currently developing drugs able to reduce succinate to improve metabolism and reduce inflammation, being our first clinical indication type 2 diabetes.
We are developing first-in-class, gut- restricted, monitorable, succinate-modulating therapies as a new opportunity for patients with metabolic and inflammatory diseases.
Specific succinate consuming bacteria is associated to high levels of circulating succinateWe have demonstrated that intestinal succinate is a relevant source of circulating succinate, thus setting the stage for the development of our propietary gut-restricted succinate-decreasing therapies to treat inflammatory and metabolic diseases, being type 2 diabetes our first clinical indication.
Fields related:
Hypertension
Cancer
Type 2 Diabetes
Crohn's Disease
Ischemic Heart Disease
Obesity
Nonalcoholic Fatty Liver
We are developing first-in-class, gut- restricted, monitorable, succinate-modulating therapies as a new opportunity for patients with metabolic and inflammatory diseases.
Specific succinate consuming bacteria is associated to high levels of circulating succinateWe have demonstrated that intestinal succinate is a relevant source of circulating succinate, thus setting the stage for the development of our propietary gut-restricted succinate-decreasing therapies to treat inflammatory and metabolic diseases, being type 2 diabetes our first clinical indication.
Fields related:
Hypertension
Cancer
Type 2 Diabetes
Crohn's Disease
Ischemic Heart Disease
Obesity
Nonalcoholic Fatty Liver